Table 2.
Comparison of BL/BLI Agents.
| BL/BLI | FDA-approved indications | FDA-approved populations | Usual dosing | Infusion time | Modifications for organ impairment | Sodium contenta | Common ADE |
|---|---|---|---|---|---|---|---|
| Ceftazidime-avibactam16 | cUTI, acute pyelonepthritis, HAP/VAP, and cIAI (in combination with metronidazole) | Adults, pediatrics (3 months or older) | 2.5 g IV q8h | 2 hours | Renal | 146-596 mg | Diarrhea, nausea, vomiting, rash, and infusion-site reaction |
| Meropenem-vaborbactam58 | cUTI | Adults | 4 g IV q8h | 3 hours | Renal | 2500-9000 mg | Headache, diarrhea, and infusion-site reaction |
| Imipenem/cilastatin-relebactam55 | cUTI, acute pyelonephritis, and cIAI | Adults | 1.25 g IV q6h | 30 minutes | Renal | 37.5-937.5 mg | Diarrhea, nausea, vomiting, headache, and infusion-site reaction |
Abbreviations: BL/BLI, β-lactam/β-lactamase; FDA, Food and Drug Administration; ADE, adverse drug event; cUTI, complicated urinary tract infection; IV, intravenous; HAP/VAP, hospital-/ventilator-acquired pneumonia; cIAI, complicated intraabdominal infection; q6h, every 6 hours; q8h, every 8 hours.
a
Total sodium content per dose of the final preparation depending on dose, diluent, and final volume desired.